Advertisement

Neonatology pp 1079-1091 | Cite as

Patent Ductus Arteriosus

  • Bart Van Overmeire
Reference work entry

Abstract

Patent ductus arteriosus (PDA) continues to be a frequent complication of extremely premature birth, despite the more generalized use of antenatal steroids, postnatal surfactant administration, and the improvement of noninvasive ventilatory strategies. Its incidence is inversely related to gestational age, such that it affects almost 60% of infants less than 28 weeks’ gestation. Spontaneous closure of the ductus occurs in 30% of infants with very low birth weight (<1500 g). When the PDA is hampering the neonate’s well-being, judicious evaluation and tailoring of the best therapeutic strategy should be performed. Ibuprofen actually seems to be the preferred drug for pharmacological treatment because of its favorable risk/benefit ratio; the therapeutic response of the most immature infants however is limited. Surgical ligation of the duct should be considered as a backup treatment due to the risks of serious complications during and after the procedure.

References

  1. Abbasi S, Hirsch D, Davis J et al (2000) Effect of single versus multiple courses of antenatal corticosteroids on maternal and neonatal outcome. Am J Obstet Gynecol 182:1243–1249PubMedCrossRefGoogle Scholar
  2. Ahlfors CE (2004) Effect of ibuprofen on bilirubin-albumin binding. J Pediatr 144:386–388PubMedCrossRefGoogle Scholar
  3. Ahlfors CE, Marshall GD, Wolcott DK et al (2006) Measurement of unbound bilirubin by the peroxidase test using zone fluidics. Clin Chim Acta 365:78–85PubMedCrossRefGoogle Scholar
  4. Amin SB, Miravalle N (2011) Effect of ibuprofen on bilirubin-albumin binding affinity in premature infants. J Perinat Med 39:55–58PubMedCrossRefGoogle Scholar
  5. Andriessen P, Struis NC, Niemarkt H et al (2009) Furosemide in preterm infants treated with indomethacin for patent ductus arteriosus. Acta Paediatr 98:797–803PubMedCrossRefGoogle Scholar
  6. Aranda JV, Varvarigou A, Beharry K et al (1997) Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. Acta Paediatr 86:289–293PubMedCrossRefGoogle Scholar
  7. Aranda JV, Clyman R, Cox B et al (2009) A randomized, doubleblind, placebo-controlled trial on intravenous ibuprofen l-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72 hours of birth in extremely low-birth-weight infants. Am J Perinatol 26:235–245PubMedCrossRefGoogle Scholar
  8. Askie LM, Ballard RA, Cutter G et al (2010) Inhaled nitric oxide in preterm infants: a systematic review and individual patient data meta-analysis. BMC Pediatr 10:15PubMedPubMedCentralCrossRefGoogle Scholar
  9. Attridge JT, Kaufman D, Lim DS (2009) B-type natriuretic peptide to guide therapy of patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 94:F178–F182PubMedCrossRefGoogle Scholar
  10. Bancalari E, Claure N, Gonzalez A (2005) Patent ductus arteriosus and respiratory outcome in premature infants. Biol Neonate 88:192–201PubMedCrossRefGoogle Scholar
  11. Bell EF, Acarregui MJ (2008) Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev (1):CD000503Google Scholar
  12. Brion LP, Soll RF (2008) Diuretics for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev (1):CD001454Google Scholar
  13. Brooks JM, Travadi JN, Patole SK et al (2005) Is surgical ligation of patent ductus arteriosus necessary? The Western Australian experience of conservative management. Arch Dis Child 90:F235–F239CrossRefGoogle Scholar
  14. Carmo KB, Evans N, Paradisis M (2009) Duration of indomethacin treatment of the preterm patent ductus arteriosus as directed by echocardiography. J Pediatr 155:819–822PubMedCrossRefGoogle Scholar
  15. Chandrasekharan NV, Dai H, Roos KL et al (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci 99:13926–13931PubMedCrossRefGoogle Scholar
  16. Chen S, Tacy T, Clyman R (2010) How useful are B-type natriuretic peptide measurements for monitoring changes in patent ductus arteriosus shunt magnitude? J Perinatol 30:780–785PubMedCrossRefGoogle Scholar
  17. Chiruvolu A, Punjwani P, Ramaciotti C (2009) Clinical and echocardiographic diagnosis of patent ductus arteriosus in premature neonates. Early Hum Dev 85:147–149PubMedCrossRefGoogle Scholar
  18. Choi BM, Lee KH, Eun BL et al (2005) Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 115:e255–e261PubMedCrossRefGoogle Scholar
  19. Chorne N, Jegatheesan P, Lin E et al (2007a) Risk factors for persistent ductus arteriosus patency during indomethacin treatment. J Pediatr 151:629–634PubMedCrossRefGoogle Scholar
  20. Chorne N, Leonard C, Piecuch R, Clyman RI (2007b) Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics 119:1165–1174PubMedCrossRefGoogle Scholar
  21. Christmann V, Liem KD, Semmekrot BA, van de Bor M (2002) Changes in cerebral, renal and mesenteric blood flow velocity during continuous and bolus infusion of indomethacin. Acta Paediatr 91:440–446PubMedCrossRefGoogle Scholar
  22. Clyman RI (1996) Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies. J Pediatr 128:601–607PubMedCrossRefGoogle Scholar
  23. Clyman R, Chemtob S (2010) Vessel remodeling in the newborn: platelets fill the gap. Nat Med 16:33–35PubMedCrossRefGoogle Scholar
  24. Clyman RI, Roman C (2007) The effects of caffeine on the preterm sheep ductus arteriosus. Pediatr Res 62:167–169PubMedCrossRefGoogle Scholar
  25. Clyman RI, Waleh N, Black SM et al (1998) Regulation of ductus arteriosus patency by nitric oxide in fetal lambs: the role of gestation oxygen tension and vasa vasorum. Pediatr Res 43:633–644PubMedCrossRefGoogle Scholar
  26. Clyman RI, Chen YQ, Chemtob S et al (2001) In utero remodeling of the fetal lamb ductus arteriosus: the role of antenatal indomethacin and avascular zone thickness on vasa vasorum proliferation, neointima formation, and cell death. Circulation 103:1806–1812PubMedCrossRefGoogle Scholar
  27. College of Physicians for the Mother and Newborn, Section Neonatology. Federal Public Health Services, BelgiumGoogle Scholar
  28. Coombs RC, Morgan ME, Durbin GM et al (1990) Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin. Arch Dis Child 65:1067–1071PubMedPubMedCentralCrossRefGoogle Scholar
  29. Cooper-Peel C, Brodersen R, Robertson A (1996) Does ibuprofen affect bilirubin-albumin binding in newborn infant serum? Pharmacol Toxicol 79:297–299PubMedCrossRefGoogle Scholar
  30. Corazza MS, Davis RF, Merrit TA et al (1984) Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus. J Pediatr 105:292–296PubMedCrossRefGoogle Scholar
  31. de Vries NK, Jagroep FK, Jaarsma AS et al (2005) Continuous indomethacin infusion may be less effective than bolus infusions for ductal closure in very low birth weight infants. Am J Perinatol 2:71–75CrossRefGoogle Scholar
  32. de Waal K, Kluckow M (2010) Functional echocardiography; from physiology to treatment. Early Hum Dev 86:149–154PubMedCrossRefGoogle Scholar
  33. del Moral T, Gonzalez-Quintero VH, Claure N et al (2007) Antenatal exposure to magnesium sulfate and the incidence of patent ductus arteriosus in extremely low birth weight infants. J Perinatol 27:154–157CrossRefGoogle Scholar
  34. Diot C, Kibleur Y, Desfrere L (2010) Effect of ibuprofen on bilirubin-albumin binding in vitro at concentrations observed during treatment of patent ductus arteriosus. Early Hum Dev 86:315–317PubMedCrossRefGoogle Scholar
  35. Doyle LW, Ehrenkranz RA, Halliday HL (2010) dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 98:217–224PubMedCrossRefGoogle Scholar
  36. Echtler K, Stark K, Lorenz M et al (2010) Platelets contribute to postnatal occlusion of the ductus arteriosus. Nat Med 16:75–82PubMedCrossRefGoogle Scholar
  37. El Hajjar M, Vaksmann G, Rakza T et al (2005) Severity of the ductal shunt: a comparison of different markers. Arch Dis Child Fetal Neonatal Ed 90:F419–F422PubMedPubMedCentralCrossRefGoogle Scholar
  38. El-Khuffash AF, Molloy EJ (2008) Influence of a patent ductus arteriosus on cardiac troponin t levels in preterm infants. J Pediatr 153:350–353PubMedCrossRefGoogle Scholar
  39. Evans N (2003) Current controversies in the diagnosis and treatment of patent ductus arteriosus in preterm infants. Adv Neonatal Care 3:168–177PubMedCrossRefGoogle Scholar
  40. Fanaroff AA, Stoll BJ, Wright LL et al (2007) Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 196(147):e1–e8Google Scholar
  41. Fowlie PW, Davis PG, McGuire W (2010) Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev (7):CD000174Google Scholar
  42. Gal P, Ransom JL, Weaver RL et al (1991) Indomethacin pharmacokinetics in neonates: the value of volume of distribution as a marker of permanent patent ductus arteriosus closure. Ther Drug Monit 13:42–45PubMedCrossRefGoogle Scholar
  43. Gersony WM, Peckham GJ, Ellison RC et al (1983) Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 102:895–906PubMedCrossRefGoogle Scholar
  44. Gonzalez A, Sosenko IR, Chandar J et al (1996) Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr 128:470–478PubMedCrossRefGoogle Scholar
  45. Gournay V, Savagner C, Thiriez G et al (2002) Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. Lancet 359:1486–1488PubMedCrossRefGoogle Scholar
  46. Gournay V, Roze JC, Kuster A et al (2004) Prophylactic ibuprofen versus placebo in very premature infants: a randomised, doubleblind, placebo-controlled trial. Lancet 364:1939–1944PubMedCrossRefGoogle Scholar
  47. Green TP, Thompson TR, Johnson DE, Lock JE (1983) Furosemide promotes patent ductus arteriosus in premature infants with the respiratory-distress syndrome. N Engl J Med 308:743–748PubMedCrossRefGoogle Scholar
  48. Guimarães H, Rocha G, Tomé T et al (2009) Non-steroid anti-inflammatory drugs in the treatment of patent ductus arteriosus in European newborns. J Matern Fetal Neonatal Med 22(Suppl 3):77–80PubMedCrossRefGoogle Scholar
  49. Halliday HL, Patterson CC, Halahakoon CW, Behalf of the European Multicenter Steroid Study Group (2001) A multicenter, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide. Pediatrics 107:232–240PubMedCrossRefGoogle Scholar
  50. Hammerman C, Glaser J, Kaplan M et al (1998) Indomethacin tocolysis increases postnatal patent ductus arteriosus severity. Pediatrics 102:E56PubMedCrossRefGoogle Scholar
  51. Herrera C, Holberton J, Davis P (2007) Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev (2):CD003480Google Scholar
  52. Hirt D, Van Overmeire B, Treluyer JM et al (2008) An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamics study. Br J Clin Pharmacol 65:629–636PubMedPubMedCentralCrossRefGoogle Scholar
  53. Holmström H, Hall C, Thaulow E (2001) Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants. Acta Paediatr 90:184–191PubMedCrossRefGoogle Scholar
  54. Ibara S, Tokunaga M, Ikenoue T et al (1994) Histologic observation of the ductus arteriosus in premature infants with intrauterine growth retardation. J Perinatol 14:411–416PubMedGoogle Scholar
  55. Ivey KN, Srivastava D (2006) The paradoxical patent ductus arteriosus. J Clin Invest 116:2863–2865PubMedPubMedCentralCrossRefGoogle Scholar
  56. Kabra NS, Schmidt B, Roberts RS et al (2007) Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr 150:229–234PubMedCrossRefGoogle Scholar
  57. Kajino H, Chen YQ, Seidner SR et al (2001) Factors that increase the contractile tone of the ductus arteriosus also regulate its anatomic remodeling. Am J Phys Regul Integr Comp Phys 281:R291–R301Google Scholar
  58. Katayama Y, Minami H, Enomoto M et al (2010) Antenatal magnesium sulfate and the postnatal response of the ductus arteriosus to indomethacin in extremely preterm neonates. J Perinatol 31:21–24PubMedCrossRefGoogle Scholar
  59. Kluckow M, Seri I, Evans N (2008) Echocardiography and the neonatologist. Pediatr Cardiol 29:1043–1047PubMedCrossRefGoogle Scholar
  60. Koch J, Hensley G, Roy L et al (2006) Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics 117:1113–1121PubMedCrossRefGoogle Scholar
  61. Lago P, Bettiol T, Salvadori S et al (2002) Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. Eur J Pediatr 161:202–207PubMedCrossRefGoogle Scholar
  62. Lee BS, Byun SY, Chung ML et al (2009) Effect of furosemide on ductal closure and renal function in indomethacin-treated preterm infants during the early neonatal period. Acta Paediatr 98:797–803CrossRefGoogle Scholar
  63. Lemmers PMA, Toet MC, van Bel F (2008) Impact of patent ductus arteriosus and subsequent therapy with indomethacin on cerebral oxygenation in preterm infants. Pediatrics 121:142–147PubMedCrossRefGoogle Scholar
  64. Lemmers PM, Molenschot MC, Evens J et al (2010) Is cerebral oxygen supply compromised in preterm infants undergoing surgical closure for patent ductus arteriosus? Arch Dis Child Fetal Neonatal Ed 95:F429–F434PubMedCrossRefGoogle Scholar
  65. Little DC, Pratt TC, Blalock SE et al (2003) Patent ductus arteriosus in micropreemies and full-term infants: the relative merits of surgical ligation versus indomethacin treatment. J Pediatr Surg 38:492–496PubMedCrossRefGoogle Scholar
  66. Loeliger M, Inder TE, Dalitz PA et al (2009) Developmental and neuropathological consequences of ductal ligation in the preterm baboon. Pediatr Res 65:209–214PubMedPubMedCentralCrossRefGoogle Scholar
  67. Lundell BP, Sonesson SE, Cotton RB (1986) Ductus closure in preterm infants. Effects on cerebral hemodynamics. Acta Paediatr Scand Suppl 329:140–147PubMedCrossRefGoogle Scholar
  68. Malviya M, Ohlsson A, Shah S (2008) Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev (1): CD003951Google Scholar
  69. Marshall DD, Kotelchuck M, Young TE et al (1999) Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association. Pediatrics 104:1345–1350PubMedCrossRefGoogle Scholar
  70. McCurnin D, Clyman RI (2008) Effects of a patent ductus arteriosus on postprandial mesenteric perfusion in premature baboons. Pediatrics 122:e1262–e1267PubMedPubMedCentralCrossRefGoogle Scholar
  71. McCurnin D, Seidner S, Chang LY et al (2008) Ibuprofen-induced patent ductus arteriosus closure: physiologic, histologic, and biochemical effects on the premature lung. Pediatrics 121:945–956PubMedCrossRefGoogle Scholar
  72. McNamara PJ, Stewart L, Shivananda SP et al (2010) Patent ductus arteriosus ligation is associated with impaired left ventricular systolic performance in premature infants weighing less than 1000 g. J Thorac Cardiovasc Surg 140:150–157PubMedCrossRefGoogle Scholar
  73. Mercier JC, Hummler H, Durrmeyer X et al (2010) Inhaled nitric oxide for the prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial. Lancet 376:346–354PubMedCrossRefGoogle Scholar
  74. Meyers RL, Alpan G, Lin E, Clyman RI (1991) Patent ductus arteriosus, indomethacin, and intestinal distension: effects on intestinal blood flow and oxygen consumption. Pediatr Res 29:569–574PubMedCrossRefGoogle Scholar
  75. Moin F, Kennedy KA, Moya FR (2003) Risk factors predicting vasopressor use after patent ductus arteriosus ligation. Am J Perinatol 20:313–320PubMedCrossRefGoogle Scholar
  76. Mosalli R, Alfaleh K (2008) Prophylactic surgical ligation of patent ductus arteriosus for prevention of mortality and morbidity in extremely low birth weight infants. Cochrane Database Syst Rev (1):CD006181Google Scholar
  77. Mosca F, Bray M, Lattanzio M et al (1997) Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. J Pediatr 131:549–554PubMedCrossRefGoogle Scholar
  78. Mosca F, Bray M, Stucchi I, Fumagalli M (2002) Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. Lancet 360:1023–1024PubMedCrossRefGoogle Scholar
  79. Nemerofsky SL, Parravicini E, Bateman D et al (2008) The ductus arteriosus rarely requires treatment in infants 1000 grams. Am J Perinatol 25:661–666PubMedCrossRefGoogle Scholar
  80. Noori S, McCoy M, Friedlich P et al (2009) Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics 123:e138–e144PubMedCrossRefGoogle Scholar
  81. Norton ME, Merrill J, Cooper BA et al (1993) Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med 329:1602–1607PubMedCrossRefGoogle Scholar
  82. O’Donovan DJ, Baetiong A, Adams K et al (2003) Necrotizing enterocolitis and gastrointestinal complications after indomethacin therapy and surgical ligation in premature infants with patent ductus arteriosus. J Perinatol 23:286–290PubMedCrossRefGoogle Scholar
  83. Ohlsson A, Shah S (2011) Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev (7):CD004213Google Scholar
  84. Ohlsson A, Walia R, Shah S (2010) Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev (4):CD003481Google Scholar
  85. Osborn DA, Hunt RW (2007) Prophylactic postnatal thyroid hormones for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev (1):CD005948Google Scholar
  86. Paquette L, Friedlich P, Ramanathan R, Seri I (2006) Concurrent use of indomethacin and dexamethasone increases the risk of spontaneous intestinal perforation in very low birth weight neonates. J Perinatol 26:486–492PubMedCrossRefGoogle Scholar
  87. Patel J, Roberts I, Azzopardi D et al (2000) Randomized doubleblind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatr Res 47:36–42PubMedCrossRefGoogle Scholar
  88. Patole SK, Kumaran V, Travadi JN et al (2007) Does patent ductus arteriosus affect feed tolerance in preterm neonates? Arch Dis Child Fetal Neonatal Ed 92:F53–F55PubMedPubMedCentralCrossRefGoogle Scholar
  89. Perlman JM, Hill A, Volpe JJ (1981) The effect of patent ductus arteriosus on flow velocity in the anterior cerebral arteries: ductal steal in the premature newborn infant. J Pediatr 99:767–771PubMedCrossRefGoogle Scholar
  90. Pezzati M, Vangi V, Biagiotti R et al (1999) Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr 135:733–738PubMedCrossRefGoogle Scholar
  91. Rakza T, Magnenant E, Klosowski S et al (2007) Early hemodynamic consequences of patent ductus arteriosus in preterm infants with intrauterine growth restriction. J Pediatr 151:624–628PubMedCrossRefGoogle Scholar
  92. Reese J, Waleh N, Poole SD et al (2009) Chronic in utero cyclooxygenase inhibition alters PGE2-regulated ductus arteriosus contractile pathways and prevents postnatal closure. Pediatr Res 66:155–161PubMedPubMedCentralCrossRefGoogle Scholar
  93. Reese J, Veldman A, Shah L et al (2010) Inadvertent relaxation of the ductus arteriosus by pharmacologic agents that are commonly used in the neonatal period. Semin Perinatol 34:222–230PubMedPubMedCentralCrossRefGoogle Scholar
  94. Richards J, Johnson A, Fox G, Campbell M (2009) A second course of ibuprofen is effective in the closure of a clinically significant PDA in ELBW infants. Pediatrics 124:e287–e292PubMedCrossRefGoogle Scholar
  95. Robel-Tillig E, Knüpfer M, Vogtmann C (2003) Cardiac adaptation in small for gestational age neonates after prenatal hemodynamic disturbances. Early Hum Dev 72:123–129PubMedCrossRefGoogle Scholar
  96. Romagnoli C, De Carolis MP, Papacci P et al (2000) Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates. Clin Pharmacol Ther 67:676–683PubMedCrossRefGoogle Scholar
  97. Rouse DJ, Hirtz DG, Thom E et al (2008) A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 359:895–905PubMedPubMedCentralCrossRefGoogle Scholar
  98. Sanjeev S, Pettersen M, Lua J et al (2005) Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol 25:709–713PubMedCrossRefGoogle Scholar
  99. Schmidt B, Davis P, Moddemann D et al (2001) Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 344:1966–1972PubMedCrossRefGoogle Scholar
  100. Schmidt B, Roberts RS, Davis P et al (2006a) Caffeine therapy for apnea of prematurity. N Engl J Med 354:2112–2121PubMedCrossRefGoogle Scholar
  101. Schmidt B, Roberts RS, Fanaroff A et al (2006b) Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). J Pediatr 148:713–714CrossRefGoogle Scholar
  102. Schneider DJ, Moore JW (2006) Patent ductus arteriosus. Circulation 114:1873–1882PubMedCrossRefGoogle Scholar
  103. Schreiber MD, Gin-Mestan K, Marks JD et al (2003) Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 349:2099–2107PubMedCrossRefGoogle Scholar
  104. Seghaye MC, Grabitz R, Alzen G et al (1997) Thoracic sequelae after surgical closure of the patent ductus arteriosus in premature infants. Acta Paediatr 86:213–216PubMedCrossRefGoogle Scholar
  105. Sehgal A, McNamara PJ (2009) Does echocardiography facilitate determination of hemodynamic significance attributable to the ductus arteriosus? Eur J Pediatr 168:907–914PubMedCrossRefGoogle Scholar
  106. Seidner SR, Chen YQ, Oprysko PR et al (2001) Combined prostaglandin and nitric oxide inhibition produces anatomic remodeling and closure of the ductus arteriosus in the premature newborn baboon. Pediatr Res 50:365–373PubMedCrossRefGoogle Scholar
  107. Seyberth HW (1983) Effect of prolonged indomethacin therapy on renal function and selected vasoactive hormones in VLBW infants with symptomatic patent ductus arteriosus. J Pediatr 103:979–984PubMedCrossRefGoogle Scholar
  108. Shaffer CL, Gal P, Ransom JL et al (2002) Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. Crit Care Med 30:343–348PubMedCrossRefGoogle Scholar
  109. Shortland DB, Gibson NA, Levene MI et al (1990) Patent ductus arteriosus and cerebral circulation in preterm infants. Dev Med Child Neurol 32:386–393PubMedCrossRefGoogle Scholar
  110. Smith GC, Wu WX, Nijland MJ et al (2001) Effect of gestational age, corticosteroids, and birth on expression of prostanoid EP receptor genes in lamb and baboon ductus arteriosus. J Cardiovasc Pharmacol 37:697–704PubMedCrossRefGoogle Scholar
  111. Soraisham AS, Dalgleish S, Singhal N (2010) Antenatal indomethacin tocolysis is associated with an increased need for surgical ligation of patent ductus arteriosus in preterm infants. J Obstet Gynaecol Can 32:435–442PubMedCrossRefGoogle Scholar
  112. Sørensen CM, Steensberg JN, Greisen G (2010) Surgical ligation of patent ductus arteriosus in premature infants. Dan Med Bull 57:A4160PubMedGoogle Scholar
  113. Sperandio M, Beedgen B, Feneberg R et al (2005) Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below 33 weeks of gestation. Pediatrics 116:1361–1366PubMedCrossRefGoogle Scholar
  114. Stefano JL, Abbasi S, Pearlman SA et al (1991) Closure of the ductus arteriosus with indomethacin in ventilated neonates with respiratory distress syndrome; effects on pulmonary compliance and ventilation. Am Rev Respir Dis 143:236–239PubMedCrossRefGoogle Scholar
  115. Su BH, Lin HC, Chiun HY et al (2008) Comparison of ibuprofen and indomethacin for early-targeted treatment of patent ductus arteriosus in extremely premature infants: a randomized controlled trial. Arch Dis Child 93:F94–F99CrossRefGoogle Scholar
  116. Szymankiewicz M, Hodgman JE, Siassi B, Gadzinowski J (2004) Mechanics of breathing after surgical ligation of patent ductus arteriosus in newborns with respiratory distress syndrome. Biol Neonate 85:32–36PubMedCrossRefGoogle Scholar
  117. Tatli MM, Kumral A, Duman N et al (2004) Spontaneous intestinal perforation after oral ibuprofen treatment of patent ductus arteriosus in two very-low-birthweight infants. Acta Paediatr 93:999–1001PubMedCrossRefGoogle Scholar
  118. Thalji AA, Carr I, Yeh TF et al (1980) Pharmacokinetics of intravenously administered indomethacin in premature infants. J Pediatr 97:995–1000PubMedCrossRefGoogle Scholar
  119. Thomas RL, Parker GC, Van Overmeire B, Aranda JV (2005) A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. Eur J Pediatr 164:135–140PubMedCrossRefGoogle Scholar
  120. Toyoshima K, Momma K, Nakanishi T (2010) In vivo dilatation of the ductus arteriosus induced by furosemide in the rat. Pediatr Res 67:173–176PubMedCrossRefGoogle Scholar
  121. Travadi J, Simmer K, Ramsay J et al (2006) Patent ductus arteriosus in extremely preterm infants receiving phototherapy: does shielding the chest make a difference? A randomized, controlled trial. Acta Paediatr 95:1418–1423PubMedCrossRefGoogle Scholar
  122. Van Overmeire B, Follens I, Hartmann S et al (1997) Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child 76:F179–F184CrossRefGoogle Scholar
  123. Van Overmeire B, Smets K, Lecoutere D et al (2000) A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 343:674–681PubMedCrossRefGoogle Scholar
  124. Van Overmeire B, Van de Broek H, Van Laer P et al (2001a) Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. J Pediatr 138:205–211PubMedCrossRefGoogle Scholar
  125. Van Overmeire B, Touw D, Schepens PJC et al (2001b) Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. Clin Pharmacol Ther 70:336–343PubMedCrossRefGoogle Scholar
  126. Van Overmeire B, Allegaert K, Casaer A et al (2004a) Prophylactic ibuprofen in premature infants: a multicentre, randomised, doubleblind, placebo-controlled trial. Lancet 364:1945–1954PubMedCrossRefGoogle Scholar
  127. Van Overmeire B, Vanhagendoren S, Schepens PJ, Ahlfors CE (2004b) The influence of ibuprofen-lysine on unbound bilirubin plasma levels in preterm neonates. Pediatr Res 55:474AGoogle Scholar
  128. Watterberg KL, Scott SM, Backstrom C et al (2000) links between early adrenal function and respiratory outcome in preterm infants: airway inflammation and patent ductus arteriosus. Pediatrics 105:320–324PubMedCrossRefGoogle Scholar
  129. Watterberg KL, Gerdes JS, Cole CH et al (2004) Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 114:1649–1657PubMedCrossRefGoogle Scholar
  130. Yokoyama U, Minamisawa S, Quan H et al (2006) Chronic activation of the prostaglandin receptor EP4 promotes hyaluronan-mediated neointimal formation in the ductus arteriosus. J Clin Invest 116:3026–3034PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Bart Van Overmeire
    • 1
  1. 1.Neonatology ServiceErasmus Hospital Université Libre de BruxellesBrusselsBelgium

Personalised recommendations